Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ARDY DAVARIFAR

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1205221603
CMS profile
11418443
Location
KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,774.60

127 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,774.60 127

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ARDY DAVARIFAR

NPI 1205221603 · CMS profile ID 11418443

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205221603?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ARDY DAVARIFAR, NPI 1205221603, CMS profile ID 11418443. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205221603?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ARDY DAVARIFAR, NPI 1205221603, CMS profile ID 11418443. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205221603?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ARDY DAVARIFAR, NPI 1205221603, CMS profile ID 11418443, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–127 of 127 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1205221603?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

127 matching records · $2,774.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 127 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–127 of 127.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $20.6403/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101255377 CMS
Genentech USA, Inc. $15.6003/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132978373 CMS
Astellas Pharma US Inc $19.7102/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139314674 CMS
Celgene Corporation $26.6202/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101091353 CMS
ABBVIE INC. $18.3802/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103604744 CMS
PFIZER INC. $17.3302/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131907639 CMS
Incyte Corporation $17.7002/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141304607 CMS
Celgene Corporation $15.8302/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101091351 CMS
BeiGene USA, Inc. $16.9502/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120866868 CMS
Merck Sharp & Dohme LLC $18.8202/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141921692 CMS
TerSera Therapeutics LLC $24.5802/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144712921 CMS
Gilead Sciences, Inc. $17.5302/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133798263 CMS
E.R. Squibb & Sons, L.L.C. $9.8402/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101255373 CMS
Merck Sharp & Dohme LLC $26.8602/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141848652 CMS
Novartis Pharmaceuticals Corporation $30.6702/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086811147 CMS
Incyte Corporation $23.6702/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141228182 CMS
Deciphera Pharmaceuticals Inc. $21.0402/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145872889 CMS
Novartis Pharmaceuticals Corporation $21.1002/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086811155 CMS
Daiichi Sankyo Inc. $24.3302/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089413465 CMS
Genmab U.S., Inc. $24.0101/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126824491 CMS
GlaxoSmithKline, LLC. $15.5301/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115894357 CMS
Daiichi Sankyo Inc. $26.3901/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089413463 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.1901/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144956037 CMS
Gilead Sciences, Inc. $17.2501/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133798261 CMS
EMD Serono, Inc. $21.3001/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120220407 CMS
Coherus Biosciences Inc. $13.9901/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147273868 CMS
JAZZ PHARMACEUTICALS INC. $29.7501/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150204150 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $507.46 18
PY2023 $4,923.27 143
PY2024 $2,774.60 127
PY2025 $9,024.52 137

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $816.64 2
PY2025 Principal investigator $837,812.71 196
PY2024 Principal investigator $287,957.77 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

198 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $102,711.71 12/31/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Follow No dispute reported 06/30/2026 1232924166
Principal investigator 1 Janssen Research & Development, LLC $646.00 12/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175348684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24.20 12/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 12/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 12/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,938.51 12/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140349
Principal investigator 1 Genmab A/S $935.00 12/12/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926913
Principal investigator 1 Genmab A/S $725.00 12/12/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926929
Principal investigator 1 Genmab A/S $318.00 12/12/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926992
Principal investigator 1 Genmab A/S $5,950.00 12/12/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927066
Principal investigator 1 Genmab A/S $4,871.00 12/12/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927082
Principal investigator 1 Genmab A/S $298.00 12/12/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927086
Principal investigator 1 BioNTech SE $2,220.20 12/11/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014225
Principal investigator 1 Genmab A/S $298.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926909
Principal investigator 1 Genmab A/S $5,950.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926920
Principal investigator 1 Genmab A/S $5,950.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926925
Principal investigator 1 Genmab A/S $132.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926955
Principal investigator 1 Genmab A/S $4,871.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926968
Principal investigator 1 Genmab A/S $298.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926983
Principal investigator 1 Genmab A/S $935.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927005
Principal investigator 1 Genmab A/S $935.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927010
Principal investigator 1 Genmab A/S $725.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927014
Principal investigator 1 Genmab A/S $725.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927037
Principal investigator 1 Genmab A/S $4,871.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927060
Principal investigator 1 Genmab A/S $69.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927079
Principal investigator 1 Genmab A/S $298.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927097
Principal investigator 1 Genmab A/S $298.00 12/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927107
Principal investigator 1 BioNTech SE $500.00 12/04/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014341
Principal investigator 1 BioNTech SE $500.00 11/26/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014343
Principal investigator 1 BioNTech SE $500.00 11/26/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,246.64 11/26/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140309
Principal investigator 1 Genmab A/S $500.00 11/25/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926979
Principal investigator 1 Genmab A/S $725.00 11/21/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926942
Principal investigator 1 Genmab A/S $106.00 11/21/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926973
Principal investigator 1 Genmab A/S $6,588.00 11/21/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927048
Principal investigator 1 Genmab A/S $500.00 11/21/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927056
Principal investigator 1 Genmab A/S $4,871.00 11/21/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927093
Principal investigator 1 BioNTech SE $2,121.60 11/20/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014227
Principal investigator 1 BioNTech SE $410.00 11/20/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014327
Principal investigator 1 BioNTech SE $200.00 11/20/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,531.53 11/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 11/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,381.98 11/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140291
Principal investigator 1 Genmab A/S $500.00 11/12/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926960
Principal investigator 1 BioNTech SE $10,780.00 11/06/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,761.40 11/06/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140279
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,400.00 11/05/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) No dispute reported 06/30/2026 1185554689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,573.56 10/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140239
Principal investigator 1 BioNTech SE $2,220.20 10/23/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,652.51 10/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140229
Principal investigator 1 Genmab A/S $53.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926938
Principal investigator 1 Genmab A/S $53.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926947
Principal investigator 1 Genmab A/S $255.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926951
Principal investigator 1 Genmab A/S $3,464.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926964
Principal investigator 1 Genmab A/S $53.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926988
Principal investigator 1 Genmab A/S $3,464.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926996
Principal investigator 1 Genmab A/S $6,728.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927000
Principal investigator 1 Genmab A/S $53.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927022
Principal investigator 1 Genmab A/S $3,464.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927026
Principal investigator 1 Genmab A/S $255.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927030
Principal investigator 1 Genmab A/S $6,728.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927034
Principal investigator 1 Genmab A/S $6,474.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927041
Principal investigator 1 Genmab A/S $3,464.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927045
Principal investigator 1 Genmab A/S $3,464.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927052
Principal investigator 1 Genmab A/S $53.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927063
Principal investigator 1 Genmab A/S $6,826.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927069
Principal investigator 1 Genmab A/S $6,826.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927073
Principal investigator 1 Genmab A/S $3,464.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927077
Principal investigator 1 Genmab A/S $6,334.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927089
Principal investigator 1 Genmab A/S $6,588.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927101
Principal investigator 1 Genmab A/S $6,474.00 10/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.80 10/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,528.80 10/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,528.80 10/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140225
Principal investigator 1 Janssen Research & Development, LLC $4,950.00 10/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175348790
Principal investigator 1 BioNTech SE $1,541.05 10/09/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,740.29 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140207
Principal investigator 1 BioNTech SE $4,049.40 10/03/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014221
Principal investigator 1 BioNTech SE $4,900.00 10/03/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014329
Principal investigator 1 BioNTech SE $4,900.00 10/03/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014331
Principal investigator 1 BioNTech SE $5,880.00 10/03/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014333
Principal investigator 1 BioNTech SE $500.00 10/03/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,528.80 10/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9.32 10/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 10/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,106.70 10/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140201
Principal investigator 1 Genmab A/S $5,950.00 10/02/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926917
Principal investigator 1 Genmab A/S $500.00 10/02/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926933
Principal investigator 1 Genmab A/S $935.00 10/02/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927019
Principal investigator 1 BioNTech SE $2,657.00 09/23/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-06 No dispute reported 06/30/2026 1249014207
Principal investigator 1 BioNTech SE $750.00 09/23/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-06 No dispute reported 06/30/2026 1249014209
Principal investigator 1 BioNTech SE $11,595.70 09/18/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,186.80 09/18/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140080
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,470.00 09/18/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24.20 09/18/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,068.62 09/18/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140091
Principal investigator 1 Eli Lilly and Company $19,500.00 09/08/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187872213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,078.26 09/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184140035
Principal investigator 1 Janssen Research & Development, LLC $11,554.00 09/01/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175348706
Principal investigator 1 BioNTech SE $7,056.70 08/26/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9.32 08/26/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 08/26/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139974
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 08/26/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139978
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,122.17 08/26/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139982
Principal investigator 1 BioNTech SE $7,663.60 08/21/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014199
Principal investigator 1 BioNTech SE $500.00 08/21/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,208.64 08/21/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139963
Principal investigator 1 BioNTech SE $7,056.70 08/14/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,106.82 08/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139952
Principal investigator 1 Janssen Research & Development, LLC $3,525.00 08/11/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175348662
Principal investigator 1 Janssen Research & Development, LLC $4,950.00 08/11/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175348775
Principal investigator 1 Janssen Research & Development, LLC $516.00 08/11/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175348827
Principal investigator 1 BioNTech SE $7,155.30 08/07/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,301.45 08/07/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139880
Principal investigator 1 Genmab A/S $104.00 08/06/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926900
Principal investigator 1 Genmab A/S $735.00 08/06/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926904
Principal investigator 1 Janssen Research & Development, LLC $3,511.00 08/01/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175348768
Principal investigator 1 Janssen Research & Development, LLC $8,475.00 08/01/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175348819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.80 07/31/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139864
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12.10 07/31/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,008.68 07/31/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139871
Principal investigator 1 BioNTech SE $17,255.85 07/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014201
Principal investigator 1 Janssen Research & Development, LLC $16,273.00 07/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175348784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,616.20 07/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,912.60 07/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,616.20 07/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,912.60 07/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 07/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139851
Principal investigator 1 BioNTech SE $7,663.60 07/17/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014377
Principal investigator 1 BioNTech SE $7,663.60 07/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,167.77 07/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139810
Principal investigator 1 BioNTech SE $11,393.40 07/03/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12.10 07/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,724.52 07/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139798
Principal investigator 1 BioNTech SE $97.00 07/01/2025 Non-covered Recipient Entity
University of Tennessee Medical Center
BNT327-03 No dispute reported 06/30/2026 1249011582
Principal investigator 1 BioNTech SE $97.00 07/01/2025 Non-covered Recipient Entity
University of Tennessee Medical Center
BNT327-03 No dispute reported 06/30/2026 1249011614
Principal investigator 1 Janssen Research & Development, LLC $16,180.00 07/01/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175348693
Principal investigator 1 BioNTech SE $2,500.00 06/24/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-06 No dispute reported 06/30/2026 1249014357
Principal investigator 1 BioNTech SE $5,000.00 06/24/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-06 No dispute reported 06/30/2026 1249014359
Principal investigator 1 BioNTech SE $2,900.00 06/24/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-06 No dispute reported 06/30/2026 1249014361
Principal investigator 1 BioNTech SE $12,000.00 06/24/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-06 No dispute reported 06/30/2026 1249014363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,154.80 06/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 06/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.74 06/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,854.00 06/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139716
Principal investigator 1 Janssen Research & Development, LLC $4,201.00 06/16/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175348677
Principal investigator 1 Janssen Research & Development, LLC $4,950.00 06/16/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175348722
Principal investigator 1 Janssen Research & Development, LLC $22,400.00 06/16/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175348753
Principal investigator 1 BioNTech SE $6,656.35 06/12/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,902.79 06/12/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139619
Principal investigator 1 BioNTech SE $2,151.35 06/05/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,353.98 06/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139617
Recipient Regeneron Pharmaceuticals, Inc. $457.00 05/31/2025 Covered Recipient Physician REGN7075 Clinical Development Program No dispute reported 06/30/2026 1184116835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $639.94 05/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 05/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 05/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.64 05/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,266.34 05/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,504.94 05/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139489
Principal investigator 1 Janssen Research & Development, LLC $26,000.00 05/20/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175348737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,411.84 05/15/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,652.51 05/08/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139473
Principal investigator 1 Genmab A/S $500.00 05/02/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235926896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $898.57 04/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,313.60 04/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,215.20 04/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 04/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,320.13 04/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139443
Principal investigator 1 BioNTech SE $2,900.00 04/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014353
Principal investigator 1 BioNTech SE $12,000.00 04/10/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-03 No dispute reported 06/30/2026 1249014355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,717.04 04/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139425
Principal investigator 1 Eli Lilly and Company $516.18 03/25/2025 Non-covered Recipient Entity
UNIVERSITY OF TENNESSEE
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187891582
Recipient Regeneron Pharmaceuticals, Inc. $359.64 03/25/2025 Covered Recipient Physician REGN7075 Clinical Development Program No dispute reported 06/30/2026 1184116833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.28 03/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $150.00 03/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,417.44 03/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,950.46 03/06/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139413
Principal investigator 1 BioNTech SE $98.10 03/01/2025 Non-covered Recipient Entity
University of Tennessee Medical Center
BNT327-03 No dispute reported 06/30/2026 1249011578
Principal investigator 1 BioNTech SE $97.00 03/01/2025 Non-covered Recipient Entity
University of Tennessee Medical Center
BNT327-06 No dispute reported 06/30/2026 1249011580
Principal investigator 1 BioNTech SE $97.00 03/01/2025 Non-covered Recipient Entity
University of Tennessee Medical Center
BNT327-06 No dispute reported 06/30/2026 1249011604
Principal investigator 1 Amgen Inc. $2,717.45 02/21/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy No dispute reported 06/30/2026 1246637568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 02/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139411
Principal investigator 1 Genmab A/S $500.00 02/14/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927110
Principal investigator 1 Genmab A/S $12,500.00 02/14/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927113
Principal investigator 1 Genmab A/S $2,500.00 02/14/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927117
Principal investigator 1 Genmab A/S $2,900.00 02/14/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927121
Principal investigator 1 Genmab A/S $2,500.00 02/14/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927125
Principal investigator 1 Genmab A/S $2,500.00 02/14/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,722.34 02/06/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139405
Principal investigator 1 BioNTech SE $72.73 02/01/2025 Non-covered Recipient Entity
University of Tennessee Medical Center
BNT327-03 No dispute reported 06/30/2026 1249011572
Principal investigator 1 BioNTech SE $42.00 02/01/2025 Non-covered Recipient Entity
University of Tennessee Medical Center
BNT327-03 No dispute reported 06/30/2026 1249011574
Principal investigator 1 BioNTech SE $97.00 02/01/2025 Non-covered Recipient Entity
University of Tennessee Medical Center
BNT327-03 No dispute reported 06/30/2026 1249011576
Principal investigator 1 BioNTech SE $97.00 02/01/2025 Non-covered Recipient Entity
University of Tennessee Medical Center
BNT327-06 No dispute reported 06/30/2026 1249011598
Principal investigator 1 BioNTech SE $97.00 02/01/2025 Non-covered Recipient Entity
University of Tennessee Medical Center
BNT327-06 No dispute reported 06/30/2026 1249011600
Principal investigator 1 BioNTech SE $97.00 02/01/2025 Non-covered Recipient Entity
University of Tennessee Medical Center
BNT327-03 No dispute reported 06/30/2026 1249011602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,313.60 01/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,215.20 01/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184139369
Principal investigator 1 Eli Lilly and Company $1,433.87 01/27/2025 Non-covered Recipient Entity
UNIVERSITY OF TENNESSEE
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187890580